1 | 0,5 MG fingolimod | - | - | - | - | 1件: 13 13 💬
|
2 | Fingolimod | 1件: Fingolimod Fingolimod (Fingolimodum) | 3件: Fingolimod hydrochloride
Fingolimod hydrochloride
(Fingolimod hydrochloride, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE),
Fingolimod
(Fingolimod),
Fingolimod lauryl sulfate
(Fingolimod lauryl sulfate) 💬
| 1件: S1PR1 S1PR1 💬
| 4件: Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 13 13, 14, 156 💬
|
3 | Fingolimod 0.5 MG | 1件: Fingolimod Fingolimod (Fingolimodum) | 3件: Fingolimod hydrochloride
Fingolimod hydrochloride
(Fingolimod hydrochloride, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE),
Fingolimod
(Fingolimod),
Fingolimod lauryl sulfate
(Fingolimod lauryl sulfate) 💬
| 1件: S1PR1 S1PR1 💬
| 4件: Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬
|
4 | Fingolimod 0.5MG | 1件: Fingolimod Fingolimod (Fingolimodum) | 3件: Fingolimod hydrochloride
Fingolimod hydrochloride
(Fingolimod hydrochloride, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE),
Fingolimod
(Fingolimod),
Fingolimod lauryl sulfate
(Fingolimod lauryl sulfate) 💬
| 1件: S1PR1 S1PR1 💬
| 4件: Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬
|
5 | Fingolimod 1.25 MG | 1件: Fingolimod Fingolimod (Fingolimodum) | 3件: Fingolimod hydrochloride
Fingolimod hydrochloride
(Fingolimod hydrochloride, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE),
Fingolimod
(Fingolimod),
Fingolimod lauryl sulfate
(Fingolimod lauryl sulfate) 💬
| 1件: S1PR1 S1PR1 💬
| 4件: Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬
|
6 | Fingolimod hydrochloride | 1件: Fingolimod Fingolimod (Fingolimodum) | 3件: Fingolimod hydrochloride
Fingolimod hydrochloride
(Fingolimod hydrochloride, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE),
Fingolimod
(Fingolimod),
Fingolimod lauryl sulfate
(Fingolimod lauryl sulfate) 💬
| 1件: S1PR1 S1PR1 💬
| 4件: Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 14 💬
|
7 | Fingolimodi | - | - | - | - | 1件: 13 13 💬
|
8 | Glatiramer acetate, interferons (intramuscular, subcutaneous, pegylated) teriflunomide, fumarates (dimethyl, diroximel, monomethyl) fingolimod, siponimod, ozanimod, ponesimod | 1件: Glatiramer Glatiramer | 1件: Glatiramer acetate
Glatiramer acetate
💬
| 20件: MHC1 MHC1, MHC1, MHC1, MHC1, MHC1, MHC1, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2, MHC2 💬
| 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 💬
|
9 | Hidrocloruro DE fingolimod | 1件: Fingolimod Fingolimod (Fingolimodum) | 3件: Fingolimod hydrochloride
Fingolimod hydrochloride
(Fingolimod hydrochloride, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE),
Fingolimod
(Fingolimod),
Fingolimod lauryl sulfate
(Fingolimod lauryl sulfate) 💬
| 1件: S1PR1 S1PR1 💬
| 4件: Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 14 💬
|
10 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | - | - | - | - | 1件: 13 13 💬
|